Compumedics Sees Fiscal Year 2026 EBITDA of Up to AU$7 Million

MT Newswires Live04-21

Compumedics (ASX:CMP) said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$5.5 million to AU$7 million, according to a Tuesday Australian bourse filing.

The company expects full fiscal year revenue of about AU$62 million to AU$65 million, representing growth of about 22% to 28% in fiscal year 2025.

The company said liquidity has been strengthened with material magnetoencephalography (MEG) cash receipts in the fiscal third quarter and expanded working capital facilities providing AU$10 million to AU$11 million of available headroom.

Revenue conversion has been impacted by timing factors, including MEG installation scheduling delays associated with conflict-related disruption in the Middle East affecting helium availability and pricing, as well as the deliberate prioritization of manufacturing readiness for Somfit D ahead of its full commercial rollout, the filing added.

The company's shares rose 1% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment